US › Healthcare

Zentalis Pharmaceuticals Llc (ZNTL)

US · Healthcare · Biotechnology

$4.88+4.95%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-35.4M
Profit YoY
+26.8%
EPS
$-0.50
EPS estimate
$-0.47

EPS came in at -0.50 against a street estimate of -0.47 — a miss of 7.4%.

Key statistics

Market cap
$337.4M
Forward P/E
0.0
P/B
1.85
Book value
$2.57
EPS (TTM)
$-1.74
52-week high
$6.95
52-week low
$1.21
50-day MA
$4.23
200-day MA
$2.93
Beta
1.93

Analyst view

Analysts rate Zentalis Pharmaceuticals Llc a buy (4 buy, 6 hold, 0 sell out of 10) with an average price target of $6.67.

Shareholding

Insiders
22.84%
Institutions
61.70%

Largest institutional holders

FundStake
Squadron Capital Management LLC5.66%
5AM Venture Management, LLC5.55%
Two Sigma Investments LLC4.15%
Vanguard Group Inc4.01%
Acadian Asset Management LLC4.00%
Vanguard Capital Management, LLC3.25%
Renaissance Technologies Corp2.72%
Citadel Advisors Llc2.43%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Zentalis Pharmaceuticals Llc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.